Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - kevin+nash
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Secreted UBE3A for the Treatment of Neurological Disorders
Advantages: Novel vector, composition, and method of treating a neurological disorder with UBE3A deficiency. High fidelity to human Angelman syndrome. Facilitates comprehensive symptom representation for diverse treatment investigations. Allows innovative experiments for pioneering treatment development. Summary: Angelman...
Published: 2/27/2025
|
Inventor(s):
Kevin Nash
Keywords(s):
Animal Models
,
Medical Therapeutics Gene Therapy
,
Neurodegenerative Diseases
,
Neuroscience
Category(s):
Technology Classifications > Medical > Biomedical Engineering
,
Technology Classifications > Medical > Neuroscience
UBE3A Gene Therapy for the Treatment of Tauopathies
Advantages: Reduction in Pathology Improved Memory and Cognitive Function Targeted Delivery and Brain-wide Distribution Business Summary: Alzheimer’s disease (AD) is a neurodegenerative disease that involves the accumulation of A-Beta proteins and Tau proteins within the brain and leads to cognitive impairments. The accumulation of these...
Published: 1/14/2025
|
Inventor(s):
Jazmin Pena
,
Kevin Nash
Keywords(s):
Medical Diagnostics
,
Neurodegenerative Diseases
,
Neuroscience
,
Therapeutics
Category(s):
Technology Classifications > Medical
,
Technology Classifications > Medical > Neuroscience
,
Technology Classifications > Medical > Biomedical Engineering
,
Technology Classifications > Medical > Biotechnology
,
Technology Classifications > Medical > Medical Diagnostics
,
Technology Classifications > Medical > Therapeutics